Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 113,042 shares at $64.15 ($7.2M) on 2025-08-13, disclosed to the SEC on 2025-08-13.
Scheduled sale ($7.2M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $63.01 | 18,717 | $1.2M | 16.4% |
| 2 | $63.01 | 18,717 | $1.2M | 16.4% |
| 3 | $63.60 | 1,283 | $82K | 1.1% |
| 4 | $63.60 | 1,283 | $82K | 1.1% |
| 5 | $63.24 | 13,042 | $825K | 11.5% |
| 6 | $63.24 | 13,042 |
| $825K |
| 11.5% |
| 7 | $64.00 | 6,958 | $445K | 6.2% |
| 8 | $64.15 | 14,948 | $959K | 13.3% |
| 9 | $64.15 | 14,948 | $959K | 13.3% |
| 10 | $64.83 | 5,052 | $328K | 4.6% |
| 11 | $64.83 | 5,052 | $328K | 4.6% |
| Total | $63.60 avg | 113,042 | $7.2M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |
| HALO | SELL | 2026-05-13 | $3.4M | — | Filing → |